Ugrás a tartalomra
Merck

Cardiovascular profile of loratadine.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1999-08-12)
J A Hey, M Affrime, B Cobert, W Kreutner, F M Cuss
KIVONAT

The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.

ANYAGOK
Cikkszám
Márka
Termékleírás

Sigma-Aldrich
Loratadine, ≥98% (HPLC), powder
USP
Loratadine, United States Pharmacopeia (USP) Reference Standard
Supelco
Loratadine, Pharmaceutical Secondary Standard; Certified Reference Material
Loratadine, European Pharmacopoeia (EP) Reference Standard
Loratadine for system suitability, European Pharmacopoeia (EP) Reference Standard